Physician profile
Asad Mohammad
NPI 1609193754
$76,002.10
in general payments reported to CMS, 2019-2025
32 companies · $2,400 in 2025
The $2,400 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,537 · 2020: $7,247 · 2021: $17K · 2022: $30K · 2023: $8,579 · 2024: $2,992 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,797 · Travel and Lodging: $4,159 · Entertainment: $13.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,797.21 |
| Travel and Lodging | $4,159.10 |
| Entertainment | $13.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $38,952.03 | 2019-2025 | Biomonitor, Edora 8 Dr-T, Sentus |
| Elutia, INC. | $14,097.74 | 2019-2024 | Ecm Patch,Pouch |
| Boston Scientific Corporation | $6,220.11 | 2019-2025 | Emblem Mri S-Icd, Endotak Reliance S, Bodyguardian |
| Biosense Webster, INC. | $5,627.40 | 2020-2025 | Carto 3 |
| Abbott Laboratories | $2,865.56 | 2019-2025 | Aveir, Ensite, Cardiomems |
| Medtronic, INC. | $2,125.24 | 2021-2024 | Linq II, Micra, Cobalt Dr Mri Surescan |
| Stereotaxis INC | $1,270.51 | 2019-2024 | Niobe, Genesis |
| Janssen Pharmaceuticals, INC | $1,253.81 | 2020-2024 | Xarelto |
| Cardiva Medical, INC. | $834.61 | 2019-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Astrazeneca Pharmaceuticals LP | $435.85 | 2019-2024 | Farxiga, Andexxa |
| Philips North America LLC | $399.49 | 2022-2025 | Mcot |
| Novartis Pharmaceuticals Corporation | $367.25 | 2019-2025 | |
| Amgen INC. | $245.20 | 2021-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.63 | 2021-2024 | Jardiance |
| Abiomed | $123.17 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.03 | 2020-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $116.29 | 2019-2020 | |
| Esperion Therapeutics, INC. | $109.71 | 2021 | |
| Davol INC. | $99.17 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $87.32 | 2024-2025 | Onpattro |
| Pfizer INC. | $55.98 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $52.36 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $49.57 | 2024-2025 | |
| Akcea Therapeutics, INC. | $47.99 | 2019 | |
| Baylis Medical Company INC | $47.45 | 2021 | |
| Kestra Medical Technology Services, INC. | $44.25 | 2024 | Assure Wcd |
| Smith+Nephew, INC. | $42.79 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.13 | 2020 | |
| Terumo Medical Corporation | $32.79 | 2022 | |
| Medicomp INC | $29.92 | 2025 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $24.25 | 2023 | Injectafer |
| Atricure, INC. | $14.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.